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T13th International Congress on Infectious Diseases Abstracts
Infection control: 1) Single room or cohort, 2) bar-
rier precautions, 3) avoid rectal thermometers, 4) chlorine
1000 ppm room cleaning, 5) early detection, 6) BioQuell -
experimental and 7) outbreak - control antibiotics and soap
for hand hygiene.
Prevention of relapses: Avoid ‘‘bad’’ Abx and antiperi-
staltics; role of probiotics and gastric pH control - unknown.
doi:10.1016/j.ijid.2008.05.100
34.004
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U of Sherbrooke, Sherbrooke, Canada
The epidemiology, clinical severity and case-fatality ratio
of Clostridium difﬁcile infection (CDI) changed dramati-
cally with the emergence of a toxin hyperproducing strain
(BI/NAP1/027) in North America and Europe since 2000.
These changes have stimulated the quest for novel thera-
peutic approaches, and a re-examination of the comparative
efﬁcacy of metronidazole versus oral vancomycin. Unfortu-
nately, tolevamer, the only novel treatment evaluated so
far in phase 3 trials, has proven inferior to comparators,
and metronidazole and vancomycin remain the two most
commonly used drugs. The major advantage of metron-
idazole is its low price. The major advantage of orally
administered vancomycin lies in its more favorable phar-
macokinetics. Facilitating vancomycin-resistant enterococci
colonization/infection is a potential drawback of both drugs.
The randomized controlled trials published so far used
intermediate outcomes rather than outcomes that now
preoccupy clinicians: the frequency of complications or
recurrences. Pending the development of a prospectively
validated scoring system, the IDSA/SHEA expert committee
will deﬁne severe CDI as any patient with a leukocyto-
sis ≥15000/mm3 or a creatinine increased by ≥50% from
baseline. For patients with mild-to moderate CDI (leuko-
cytosis <15000/mm3 and creatinine <1.5 X baseline), there
is no evidence that vancomycin is superior to metronida-
zole (even for intermediate outcomes), and metronidazole
should be preferred. For patients with severe CDI not
infected with BI/NAP1/027, there is reasonable evidence
that the better pharmacokinetics of vancomycin translate
into a lower probability of complications. For those infected
with BI/NAP1/027, the superiority of vancomycin remains to
be proven. About one fourth of patients treated with either
metronidazole or vancomycin will experience at least one
recurrence. There is now some evidence that the more com-
mon post-metronidazole recurrences documented recently
in some centers may have corresponded to re-infections
among patients who remained exposed in the hospital envi-
ronment.
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ervical Cancer Vaccination: The Need for Strong and
ustained Protection (invited)
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PV Types 16, 18, 45 and 31: The Most Important
ncogenic HPV Types Worldwide
.X. Bosch
Catalan Institute of Oncology IDIBELL, Barcelona, Spain
PV infections are the most common sexually transmitted
nfections. HPV types differ in transmission capacity, vir-
lence and in their ability to induce cancer. Over 90% of
PV-attributable cancers in women are cervical cancer. Most
ancers of the uterine cervix are squamous cell carcinomas,
hile adenocarcinoma represents 10-12% of the global cer-
ical cancer burden (in some countries of Europe and North
merica it amounts to over 20% of all invasive cervical can-
er).
On worldwide estimates, HPV-16 is consistently the most
ommon type (60%) in cervical cancer, followed by HPV-
8, -45 and -31. These four types combined account for
pproximately 80% of squamous cell carcinomas and 90% of
denocarcinomas. Some variability in the ranking thereafter
as been described.
Infections with HPV-16, -18, or -45 are associated with a
igher risk for progression to cancer. The prognosis of HPV-16
nd -18 is now being established by cohort studies with 10+
ears of follow-up. The probability and time to progression
o HSIL among HPV-16 and/or HPV-18 positive women with
ormal cytology is signiﬁcantly higher than for any other
f the high-risk HPV types, although the estimates for each
ndividual type other than HPV-16 and -18 have not been
rmly established.
Adenocarcinoma is not detected effectively by cervical
creening and is increasing in incidence in Europe and North
merica. It is associated with higher recurrence rates and
oor outcomes. HPV-18 and -45 account for more than 40%
f adenocarcinomas.
Among other HPV positive cancer cases, HPV-16 is the
ominant type. HPV-18 and-45 are the next most common
ypes, although the relative role of the remaining HPV types
s still to be determined.
In summary, on a worldwide scale, prevention of cervi-
al and other genital cancers would greatly beneﬁt from
accination focused on HPV-16 and -18.
oi:10.1016/j.ijid.2008.05.102
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he Value of New Adjuvant Technology
. Zepp1,∗, N. Garc¸on2,∗
Children’s Hospital, Johannes Gutenberg, Mainz, Germany
GSK, Rixensart, Belgium
he development of safe and efﬁcacious vaccines against
athogens like malaria, HIV and TB and the induction of
rotective immune responses in populations with impaired
mmunity such as the elderly remain major challenges. The
rowing understanding of the role of the innate immune sys-
em in the initial triggering of speciﬁc, adaptive immune
